Genotypic Inhibitory Quotient as Predictor of Virological Response to Ritonavir-Amprenavir in Human Immunodeficiency Virus Type 1 Protease Inhibitor-Experienced Patients

Forty-nine protease inhibitor (PI)-experienced but amprenavir (APV)-naïve patients experiencing virological failure were treated with ritonavir (RTV) (100 mg twice a day [b.i.d.]) plus APV (600 mg b.i.d.). Patients responded to therapy with a median viral load decrease of −1.32 log(10) by week 12. T...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Marcelin, Anne-Geneviève, Lamotte, Claire, Delaugerre, Constance, Ktorza, Nadine, Ait Mohand, Hocine, Cacace, Raquel, Bonmarchand, Manuela, Wirden, Marc, Simon, Anne, Bossi, Philippe, Bricaire, François, Costagliola, Dominique, Katlama, Christine, Peytavin, Gilles, Calvez, Vincent
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society for Microbiology 2003
Schlagworte:
Antiviral Agents
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC151735/
https://ncbi.nlm.nih.gov/pubmed/12543665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.47.2.594-600.2003
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge